Omalizumab rapidly improves angioedema-related quality of life in adult patients with chronic spontaneous urticaria: X-ACT study data.
P StaubachM MetzN Chapman-RotheC SiederM BräutigamMarcus MaurerKarsten WellerPublished in: Allergy (2017)
Our findings support omalizumab treatment in patients with severe H1-antihistamine-refractory CSU with angioedema.